CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

In March 2012, the 1st Nextgen China was held successfully in Shanghai. FDA, USP, national institutes for Food and Drug Control and leading pharmaceutical companies from home and abroad were invited to give presentations. More than 180 generic drug makers attended the summit. It was an unprecedentedly grand occasion and won a favorable reception.

In November 2012, over 200 decision makers from the government, generics companies and original medicine companies gathered for the 2nd Nextgen China, which was held in Beijing. They discussed the latest regulations, market conditions and technology and gave high evaluations of this summit.

In March 2013, the 3rd Nextgen China ended successfully at the Shanghai Crowne Plaza Century. During the two days of this summit, famous experts and representatives from pharmaceutical companies were invited to make speeches and over 100 experts and guests from the generic industry took part in active discussions. They gave an overview of the latest market situation and provided more cooperation opportunities.

Based on the great success of the 3 former sessions of NEXTGEN conferences, CPhI will conduct The 4th NEXTGEN China 2014 Conference from March 27-28 2014 in Shanghai. CPhI will gather all the essence and global resources into this conference to bring further information and experience sharing. This summit will provide a special session for Generics Consistency Evaluation, to summarize the evaluation work from 2013 and explore programs for 2014.

Speakers at this summit are from the two aspects of the pharmaceutical industry: Regulatory Updates and Technology & Market. In the area of regulatory updates, Mr. Wang, a researcher at the National Drug Policy & Economic Research Center (NDPE), will deliver a speech, entitled "Generics Quality Improvement In China". In the area of technology and market, national "one thousand program" distinguished expert Jeannie Zhang will give a speech on the research of APIs and technology development. Meanwhile, the committee will provide two panel discussions. On day one, the president of RDPAC, Joseph Cho, will moderate a discussion on the specific practice of generics consistency evaluation. On day two, the vice president of Huahai US will discuss the topic of how to establish strategic partnerships and breakthrough technique difficulties to improve generics market access.